- Home
- UTF vs WGS Comparison
UTF vs WGS Comparison
Compare UTF & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTF
- WGS
- Stock Information
- Founded
- UTF 2004
- WGS 2017
- Country
- UTF United States
- WGS United States
- Employees
- UTF N/A
- WGS N/A
- Industry
- UTF Finance Companies
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- UTF Finance
- WGS Technology
- Exchange
- UTF Nasdaq
- WGS Nasdaq
- Market Cap
- UTF 2.6B
- WGS 2.4B
- IPO Year
- UTF N/A
- WGS N/A
- Fundamental
- Price
- UTF $26.67
- WGS $101.60
- Analyst Decision
- UTF
- WGS Strong Buy
- Analyst Count
- UTF 0
- WGS 8
- Target Price
- UTF N/A
- WGS $91.25
- AVG Volume (30 Days)
- UTF 171.7K
- WGS 1.0M
- Earning Date
- UTF 01-01-0001
- WGS 07-29-2025
- Dividend Yield
- UTF 7.19%
- WGS N/A
- EPS Growth
- UTF N/A
- WGS N/A
- EPS
- UTF 2.84
- WGS 0.05
- Revenue
- UTF $138,636,669.00
- WGS $362,321,000.00
- Revenue This Year
- UTF N/A
- WGS $22.16
- Revenue Next Year
- UTF N/A
- WGS $19.63
- P/E Ratio
- UTF $9.16
- WGS $2,075.81
- Revenue Growth
- UTF 19.80
- WGS 48.70
- 52 Week Low
- UTF $22.05
- WGS $25.32
- 52 Week High
- UTF $26.53
- WGS $117.75
- Technical
- Relative Strength Index (RSI)
- UTF 52.57
- WGS 69.10
- Support Level
- UTF $26.39
- WGS $78.99
- Resistance Level
- UTF $26.84
- WGS $107.31
- Average True Range (ATR)
- UTF 0.26
- WGS 5.80
- MACD
- UTF -0.03
- WGS 2.07
- Stochastic Oscillator
- UTF 55.74
- WGS 81.74
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.